BeyondSpring Reports Results of Plinabulin + Docetaxel in P-III DUBLIN-3 Trial for 2L and 3L Treatment of NSCLC with EGFR Wild Type

August 4, 2021 Auto Bot BeyondSpring, NSCLC, P-III, Plinabulin, regulatory 0

Shots:

  • The P-III DUBLIN-3 trial evaluates plinabulin + docetaxel vs docetaxel alone in 599 patients with 2L & 3L NSCLC EGFR wild type, with measurable lung lesion
  • The trial met its 1EPs & 2EPs i.e improvement in OS, ORR, PFS, and OS rate @24 & 36mos. (22.1% vs 12.5% & 11.7% vs 5.3%); @48mos. OS (10.6% vs 0%), reduction in incidence of Grade 4 neutropenia (5.3% vs 27.8%)
  • The company plans to seek US FDA and NMPA approval for plinabulin + docetaxel in NSCLC based on the clinical benefit and safety profile. Additionally, the NDA submission for NSCLC indication is expected in H1’22

Click here to read full press release/ article | Ref: Globenewswire | Image: Linkedin

The post BeyondSpring Reports Results of Plinabulin + Docetaxel in P-III DUBLIN-3 Trial for 2L and 3L Treatment of NSCLC with EGFR Wild Type first appeared on PharmaShots.